Hassanpour Khodaei Sepideh, Sabetkam Shahnaz, Mazloumi Zeinab, Dizaji Asl Khadijeh, Rafat Ali
Department of Dentistry, Eastern Mediterranean University (EMU), North Cyprus Mersin 10, Famagusta, Turkey.
Department of Anatomy, Faculty of Medicine, University of Kyrenia, Kyrenia, Northern Cyprus, Turkey.
Med Oncol. 2025 Jun 28;42(8):292. doi: 10.1007/s12032-025-02869-0.
Colorectal cancer (CRC) is the third most common cancer worldwide. Despite the availability of conventional treatment options, challenges such as limited therapeutic alternatives and poor prognosis persist. Tigecycline is an inhibitor drug that blocks mitochondria-related proliferation in cancer cells and may enhance disease-free survival. We examined how Tigecycline plus radiotherapy affects CRC cell growth. Additionally, the study evaluated the expression of cancer cell markers and related genes. HCT-116 colorectal cancer cell lines were treated with the IC50 dose of Tigecycline and subsequently exposed to radiation. To evaluate the proliferation rate after treatment with IC50 dose, Ki-67 expression was analyzed using flow cytometry. Finally, the expression levels of cancer cell markers CD44 and the related genes SOX2 and OCT4 were analyzed. The results showed that Tigecycline reduced HCT-116 cell viability in a dose-dependent manner. IC50 dose of determined 93 um. Although the expression level of CD44 decreased significantly in the combination therapy groups, no significant difference was observed in Ki-67 expression among the treatment groups. Data are representative of three independent experiments. *P < 0.05. The findings suggest that combining Tigecycline with radiotherapy may have potential as a complementary strategy for colorectal cancer treatment, warranting further investigation.
结直肠癌（CRC）是全球第三大常见癌症。尽管有传统的治疗选择，但诸如治疗选择有限和预后不良等挑战仍然存在。替加环素是一种抑制剂药物，可阻断癌细胞中线粒体相关的增殖，并可能提高无病生存率。我们研究了替加环素联合放疗如何影响结直肠癌细胞的生长。此外，该研究评估了癌细胞标志物和相关基因的表达。用替加环素的IC50剂量处理HCT-116结直肠癌细胞系，随后进行辐射。为了评估用IC50剂量处理后的增殖率，使用流式细胞术分析Ki-67的表达。最后，分析癌细胞标志物CD44以及相关基因SOX2和OCT4的表达水平。结果表明，替加环素以剂量依赖性方式降低HCT-116细胞活力。确定的IC50剂量为93 μM。虽然联合治疗组中CD44的表达水平显著降低，但各治疗组之间Ki-67的表达未观察到显著差异。数据代表三个独立实验。*P < 0.05。研究结果表明，将替加环素与放疗联合使用可能作为结直肠癌治疗的一种补充策略具有潜力，值得进一步研究。
